Serzone / nefazodone

March 10, 2008

By judgment dated January 22, 2008, Madam Justice Gaudreau of the Quebec Superior Court authorized the Quebec proceeding as a class action and approved the SerzoneŽ Settlement, thereby making the Settlement effective. To view a copy of the notice advising of Court approval of the Settlement, please click here.

For further information and access to claims forms, please go to the Settlement website at SerzoneSettlement.ca.

The deadline to file claims with the Claims Administrator is May 2, 2008.

December 6, 2007

By order dated December 6, 2007, Mr. Justice Cullity of the Ontario Superior Court of Justice certified the Ontario proceeding as a national class action and approved the SerzoneŽ Settlement. British Columbia residents are included in the National Class.

In order for the Settlement to become effective it must still be approved by the Quebec Superior Court. Please note that the final day of the Claim Period has been extended from December 31, 2007 to 45 days following the Opt Out Deadline (or 90 days from the publication of the Approval Notice). The exact deadline will be known when the Quebec Superior Court approves the Settlement and will be posted on our website. For more important information, please visit SerzoneSettlement.ca.

April 16, 2007

For information regarding the settlement of the Serzone class action, please click here.

November 26, 2004

If you wish to be entered into our database of Serzone / nefazodone users please click here.

November 25, 2004

Poyner Baxter has filed a class action lawsuit against Bristol-Myers Squibb Canada Co., Bristol-Myers Squibb Company, Linson Pharma Co., Apotex Inc., Pharmel Inc., Dominion Pharmacal Inc., Novopharm Limited, Pharmascience Inc., Nupharm Inc., Ratiopharm Inc., and Genpharm Inc.

These companies manufactured and sold the drug nefazodone as an anti-depressant in Canada.   Nefazodone was marketed in Canada by Bristol-Myers Canada as Serzone  from 1994 to 2001. When Bristol-Myers patent for nefazodone expired in 2001, Linson, Apotex, Pharmel, Dominion, Novopharm, Pharmascience, Nupharm, Ratiopharm, and Genpharm also began marketing their respective generic versions of nefazodone.

The companies continued to market Serzone and nefazodone in Canada until November of 2003 when the drug was withdrawn from the market as a result of the liver damage that nefazodone was causing to many of the patients who took it.

The class action alleges that by that time, all of these companies knew, or ought to have known, about the serious risk of liver injury posed by nefazodone.

To view the complete Statement of Claim, click here.

This Web site is offered for information only and is not legal advice. Use of the site and sending or receiving information through it does not establish an attorney-client relationship. No one should act, or refrain from acting, based solely upon this information without seeking appropriate legal or other professional advice. In particular, you should obtain advice about limitation periods as it may affect your right to bring a legal action on your own behalf. Links to and from from this Web site do not state or imply a relationship between Poyner Baxter LLP and the linked entity.

Back